Guangzhou Innogen Pharmaceutical Group Co., Ltd (HKG:2591)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
42.16
+0.56 (1.35%)
Sep 3, 2025, 4:08 PM HKT

HKG:2591 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023
Period Ending
Jun '25 Dec '24 Dec '23
Selling, General & Admin
132.3486.85255.74
Research & Development
149.69102.51492.11
Other Operating Expenses
3.110.060.06
Operating Expenses
285.14189.42747.91
Operating Income
-234.65-189.42-747.91
Interest Expense
-0.43-0.87-2.32
Interest & Investment Income
3.873.824.19
Currency Exchange Gain (Loss)
0.430.70.71
Other Non Operating Income (Expenses)
0.250.219.85
EBT Excluding Unusual Items
-230.53-185.57-735.48
Gain (Loss) on Sale of Investments
8.6511.172.1
Gain (Loss) on Sale of Assets
--4.45-
Other Unusual Items
-4.15-
Pretax Income
-221.89-174.69-733.38
Net Income
-221.89-174.69-733.38
Net Income to Common
-221.89-174.69-733.38
Shares Outstanding (Basic)
420420383
Shares Outstanding (Diluted)
420420383
Shares Change (YoY)
-9.63%-
EPS (Basic)
-0.53-0.42-1.92
EPS (Diluted)
-0.53-0.42-1.92
Free Cash Flow
--166.57-176.64
Free Cash Flow Per Share
--0.40-0.46
EBITDA
-219.96-174.91-733.76
D&A For EBITDA
14.6914.5114.14
EBIT
-234.65-189.42-747.91
Source: S&P Global Market Intelligence. Standard template. Financial Sources.